fig17
![Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention](https://image.oaes.cc/90c048c1-30a0-44b1-9c79-c69588a02257/2317.fig.17.png)
Figure 17. Selected compounds that act as: (A) NTD modulators; (B) DBD inhibitors; (C) indirect inhibitors of AR and AR variants; and (D) selective androgen receptor downregulator (SARD) compounds. AR: androgen receptor; DBD: DNA-binding domain; NTD: N-terminal domain